Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11527982 | 0.83 | ABCC1 (0.56) | ABCC1TAAR1L3MBTL1AOC3SIGMAR1 | |
| SCHEMBL11528266 | 0.81 | CA12 (0.59) | ABCC1L3MBTL1LMNAMGLLCA12 | |
| SCHEMBL7670527 | 0.81 | CHRNA7 (0.59) | L3MBTL1HTT | |
| SCHEMBL7226798 | 0.78 | AOC3 (0.57) | ABCC1TAAR1AOC3SIGMAR1NPY5R | |
| SCHEMBL28128867 | 0.77 | ABCC1 (0.50) | ABCC1TAAR1L3MBTL1LMNAAOC3 | |
| SCHEMBL9732899 | 0.76 | KDM4E (0.53) | ABCC1LMNAHTT | |
| SCHEMBL2796515 | 0.75 | TAAR1 (0.52) | ABCC1TAAR1AOC3SIGMAR1NPY5R | |
| SCHEMBL14868329 | 0.73 | TAAR1 (0.46) | ABCC1TAAR1AOC3SIGMAR1NPY5R | |
| SCHEMBL1520363 | 0.73 | KMT2A (0.59) | ABCC1TAAR1AOC3NPY5RCA12 | |
| SCHEMBL12133489 | 0.72 | LTB4R (0.52) | ABCC1TAAR1L3MBTL1AOC3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11465989-B2 | Guanidine compounds and use thereof | ImmunoMet Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| US-4156735-A | SALIDIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-05-29 | — | — | US | disclosed |
| US-4118501-A | SALIDIURETIC ACTIVITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465989-B2 | Guanidine compounds and use thereof | PC, TFAM, PCK2 | ABCC1 614/4885TAAR1 4576/4885L3MBTL1 2820/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | ABCC1 614/4885TAAR1 4576/4885L3MBTL1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.